Ponatinib in CML and Ph+ ALL: Long-term efficacy and safety

Ponatinib is a highly potent agent recommended by international guidelines. Watch this video to gain insights from Dr Raymond Wong of the Division of Haematology, Department of Medicine & Therapeutics, Chinese University of Hong Kong, on ponatinib’s long-term data in chronic myeloid leukaemia (CML) and Philadelphia-positive acute lymphoblastic leukaemia (Ph+ ALL), and how to optimize its dose to improve risk-benefit profile.